CStone Pharmaceuticals-B (02616.HK) Announces Key Clinical Validation Data for CS2009 at ESMO 2026: Data from Over 300 Patients Simultaneously Validate Mechanism of Action, Safety, and Broad-Spectrum Antitumor Activity

Zhitong Finance APP News, CStone Pharmaceuticals-B (02616.HK) announced that the company's self-developed PD-1/VEGF/CTLA-4 trispecific antibody CS2009 has achieved a major clinical validation milestone, and the latest clinical data have been presented in two rapid oral presentations at the 2026 European Society for Medical Oncology (ESMO) Congress.